Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer

被引：0
|
作者：
Susan M. Farabaugh
Bonita T. Chan
Xiaojiang Cui
Robert K. Dearth
Adrian V. Lee
机构：
[1] University of Pittsburgh Cancer Institute,Women’s Cancer Research Center, Department of Pharmacology and Chemical Biology
[2] Magee Women’s Research Institute,Lester and Sue Smith Breast Center, Department of Molecular and Cellular Biology
[3] Baylor College of Medicine,undefined
来源：
Cell Communication and Signaling | / 14卷
关键词：
IRS; ErbB2; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Brk is coamplified with ErbB2 to promote proliferation in breast cancer
    Xiang, Bin
    Chatti, Kiranam
    Qiu, Haoqun
    Lakshmi, B.
    Krasnitz, Alexander
    Hicks, Jim
    Yu, Min
    Miller, W. Todd
    Muthuswamy, Senthil K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (34) : 12463 - 12468
  • [42] MiR-34a modulates ErbB2 in breast cancer
    Wang, Yilin
    Zhang, Xiaolong
    Chao, Zou
    Kung, Hsiang-Fu
    Lin, Marie C.
    Dress, Andreas
    Wardle, Fiona
    Jiang, Bing-Hua
    Lai, Lihui
    CELL BIOLOGY INTERNATIONAL, 2017, 41 (01) : 93 - 101
  • [43] Targetable ERBB2 mutations independently predict an aggressive phenotype in primary, ERBB2 non-amplified, hormone receptor positive lobular breast cancer
    Kurozumi, Sasagu
    Green, Andrew R.
    Ellis, Ian O.
    Rakha, Emad A.
    Fujii, Takaaki
    Shirabe, Ken
    Heery, David
    Zwart, Wilbert
    Oesterreich, Steffi
    Johnston, Simon J.
    CANCER RESEARCH, 2020, 80 (04)
  • [44] The potential role of the EGFR/ERBB2 heterodimer in breast cancer
    Cicenas, Jonas
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (06) : 607 - 616
  • [45] Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores
    Robbins, Charles J. J.
    Fernandez, Aileen I. I.
    Rimm, David L. L.
    JAMA ONCOLOGY, 2023, 9 (09) : 1298 - 1299
  • [46] MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
    Paulson, Amanda K.
    Linklater, Erik S.
    Berghuis, Bree D.
    App, Colleen A.
    Oostendorp, Leon D.
    Paulson, Jayne E.
    Pettinga, Jane E.
    Melnik, Marianne K.
    Woude, George F. Vande
    Graveel, Carrie R.
    MOLECULAR CANCER RESEARCH, 2013, 11 (09) : 1112 - 1121
  • [47] Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
    Eya Wolfson
    Shira Solomon
    Eran Schmukler
    Yona Goldshmit
    Ronit Pinkas-Kramarski
    Cell Death & Disease, 9
  • [48] Aberrations of ERBB2 and TOP2A genes in breast cancer
    Nielsen, Kirsten Vang
    Muller, Sven
    Moller, Susanne
    Schonau, Andreas
    Balslev, Eva
    Knoop, Ann S.
    Ejlertsen, Bent
    MOLECULAR ONCOLOGY, 2010, 4 (02) : 161 - 168
  • [49] Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
    Wolfson, Eya
    Solomon, Shira
    Schmukler, Eran
    Goldshmit, Yona
    Pinkas-Kramarski, Ronit
    CELL DEATH & DISEASE, 2018, 9
  • [50] Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells
    Lu, YH
    Zi, XL
    Zhao, YH
    Pollak, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 313 (03) : 709 - 715
12345